Diagnosing and treating NHL in teenagers and young adults

Robert Carr, MD, Guy's and St Thomas' Hospital, London, UK, discusses findings from a UK population-based study of non-Hodgkin lymphoma in teenagers and young adults, which revealed inconsistences in diagnosis and treatment in the assessed cohort. Location of treatment was examined, where there were more delayed diagnoses in smaller non-specialist hospitals. Treatment of Burkitt lymphoma (BL) in young adults was additionally examined, where treatment regimens in the UK (CODOX-M/IVAC: cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine) and Europe (LMB: vincristine, cyclophosphamide, prednisolone) were compared. The European protocol was more effective, suggesting young adults with BL should receive the pediatric LMB protocol. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).